U-VUE®
Custom Biomarkers
Pre-optimized Panels
When your assay requirements are unique, our assay development team can walk you through every step of the journey with expert guidance in creating and implementing clinical biomarker strategies.
Not sure of your perfect panel? Our in-house team of experts can partner with you to find the custom answer to your specific biological question.
Accelerate your research timelines with custom biomarkers in robust, pre-optimized panels. Empower your team to attain powerful quantitative spatial insights into the tissue microenvironment, with up to 70% reduction in project timelines.
Explore examples biomarkers that can help address specific biological hypotheses.
Checkpoints
Tumor cells use various tricks to escape the immune system, such as activating immune checkpoint pathways. Today, hundreds of clinical trials are incorporating immune checkpoint inhibitor (ICI) therapeutics.
- CD27
- CD28
- CD40
- CD70
- CD73
- CD80
- CD96
- CD155
- CTLA4
- IDO1
- LAG3
- PD-1
- PD-L1
- TIGIT
Exhaustion
T cell exhaustion arises from persistent T cell activation, which may explain why surface markers of exhausted T cells are inter-twined with activated T cells. Ex-hausted T cells start producing much lower amounts of immune response-stimulating proteins, and generally become less able to kill tumor cells.
- CD8
- CD39
- CD68
- CTLA4
- LAG3
- PD1
- TIGT
TAMs
Tumor-associated macrophages represent a major component of myeloid cells in tumors. TAMs polarize to either M1, anti-tumor activity, or M2, which leads to tumor promotion. The balance between these two polarized macrophages is important for cancer therapies and correlates with clinical outcome.
- Arg1
- CD11c
- CD163
- CD206
- CD68
- CD86
- HLA-DR
- INOS
Myeloid
Myeloid cells are potential predictive biomarkers in checkpoint blockade-treated patients. Myeloid-derived suppressor cells and monocytes, the expansion of neutrophils, eosinophils and immature myeloid cells reflect the immunosuppressive status of the TME during immunotherapy.
- Arg1
- CD11b
- CD14
- CD15
- CD16
- CD68
- CD163
- HLA-DR
Functional
These include markers that can inform the cellular functional state (e.g., Ki-67 for proliferation and granzyme B for cytotoxicity)
- CK
- Desmin
- GrzB
- Ki67
- Sox10
- TCF1/TCF7
Dendritic
DCs are mediators of the innate and adaptive immune responses. They upregulate MHC molecules and costimulatory receptors, present antigens to naive T cells, and produce polarizing cytokines that effect T cell differentiation and activation.
- CD3
- CD4
- CD11c
- CD20
- CD56
- CD68
- CD138
- Clec9a
- Clec10a
- MHC II
Stromal
The TME or stromal is a multicellular system composed of cells from mesenchymal,
endothelial, and hematopoietic origins arranged in the extracellular matrix (ECM). Secreted products from a variety of cells and components drive the intratumoral environment.
- Alpha-SMA
- CD31
- CD299
TLS
Tertiary lymphoid structures are ectopic aggregates of lymphocytes and antigen-presenting cells that develop in non-lymphoid tissues at sites of chronic inflammation. There is a close association between tumor-associated TLSs and favorable clinical outcomes in most types of cancers.
- CD3
- CD4
- CD20
- CD56
- CD68
- CD138
Cell Signaling
Therapeutic modalities inhibit tumor growth and metastasis by blocking commonly overexpressed signal transduction molecules. They comprise signalling pathways that cause profound effects on cells; apoptosis, proliferation and migration but are often aberrantly expressed in cancer cells.
- Bcl-2
- Bcl-cl
- Beta-Catenin
- Bim
- Ki67
- MCL-1
T-Cell Regulation
The crucial role of T cell lymphocytes is as the main regulators and effectors in anti-tumor immunity. Many studies have revealed their role in immune surveillance and the vital contribution made by adaptive immune cells in suppressing the formation of tumors.
- CD3
- CD4
- CD8
- CD27
- CD38
- CD45RO
- CD70
- FoxP3
- GrzB
- LAG3
- PD1
- PD-L1
TILS
Tumor infiltrating lymphocytes consist of any lymphocytic cell populations that have invaded the tumor. TILs are described in several tumor types and immune checkpoint inhibitor therapy in cancer patients has been linked to the quality and magnitude of T cell, NK cell, and B cell responses.
- CD3
- CD4
- CD8
- CD20
- CD38
- CD45RO
- CD56
- CD68
- CD335
B cells
B cells and plasma cells located in tumors can have important roles in shaping anti-tumor immune responses. B cells can present cognate tumor-derived antigens to T cells and the densities of tumor-associated plasma cells may predict improved cancer prognosis.
- BCMA
- CD19
- CD20
- CD22
- CD27
- CD38
- CD138
- Pax5
- MHC II
Don’t see your biomarker of interest? Reach out to us and we will develop the custom marker and panel for you.
Get the spatial insights that matter to you through customized biomarker panels.
Contact Sales